© 2018 Miraculo Inc. All Rights Reserved
Cannabinoids are a group of chemicals in the cannabis plant (cannabis sativa) and are said to have anti inflammatory properties. Cannabidiol (CBD) is one of the main constituents of cannabinoids and tetrahydrocannabinol (THC) is another, responsible for the psychotropic effects. Cannabinoid receptors in the endocannabinoid system allow cannabinoids to bind and work freely in the body. Cannabinoid metabolism in the body has been associated with colonic transit in patients with irritable bowel syndrome (IBS). This paper will look at the effects of dronabinol, a agonist of the cannabinoid receptor, on patients with IBS.
Here is the full scientific article if you wish to download it.
Dronabinol decreases IBS symptoms
75 patients with IBS were studied. 5 mg of Dronabinol was administered on these patients. Parameters that were measured were left colonic compliance, motility index, tone and sensation during fasting and after the meal. The results show that dronabinol decreased fasting in the left colon and increased colonic compliance. Dronabinol effects were greatest in IBS patients with diarrhea.
CBD has a colonic motility potential
Dronabinol did not alter the sensation or tone in the bowel. Dronabinol affected the fasting motility index in IBS patients. Constipation was improved in patients with IBS when dronabinol was administered. This proves that CBD dronabinol has a massive potential in becoming a colonic motility drug to treat IBS sufferers and improve bowel movement, thus improving their quality of life.